Abeona Therapeutics Inc (ABEO)vsNovartis AG ADR (NVS)
ABEO
Abeona Therapeutics Inc
$5.34
-0.37%
HEALTHCARE · Cap: $303.75M
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 972031% more annual revenue ($56.58B vs $5.82M). ABEO leads profitability with a 1223.0% profit margin vs 23.9%. ABEO trades at a lower P/E of 5.3x. NVS earns a higher WallStSmart Score of 51/100 (C-).
ABEO
Hold46
out of 100
Grade: D+
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+81.8%
Fair Value
$27.73
Current Price
$5.34
$22.39 discount
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Every $100 of equity generates 70 in profit
Keeps 1223 of every $100 in revenue as profit
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Revenue declined 100.0%
Negative free cash flow — burning cash
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABEO
The strongest argument for ABEO centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 1223.0% and operating margin at -422.7%.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : ABEO
The primary concerns for ABEO are EPS Growth, Market Cap, Revenue Growth.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Key Dynamics to Monitor
ABEO carries more volatility with a beta of 1.21 — expect wider price swings.
NVS is growing revenue faster at -0.7% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVS scores higher overall (51/100 vs 46/100), backed by strong 23.9% margins. ABEO offers better value entry with a 81.8% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Abeona Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for rare, life-threatening genetic diseases. The company is headquartered in New York, New York.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?